Deals Of The Week: Medco/United BioSource, Aspen/Sigma, Biogen/Knopp ...
Executive Summary
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.
You may also be interested in...
Novartis And Quark Partner On Phase II siRNA Drug For Kidney Damage Indications
Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.
First Deal Of Scangos Era Brings Phase II ALS Candidate To Biogen Idec
Big biotech pays $80 million to Knopp Biosciences for worldwide license to dexpramiprexole.
Aspen's Acquisition of Sigma For APAC Expansion Comes At Time Of Generics Uncertainty In Australia
TOKYO - South African firm Aspen appears on track to finalize its months-long acquisition attempt of Australia's Sigma Pharmaceuticals, shifting away from its original offer for a full acquisition to a leaner deal in which Aspen will gain Sigma's pharmaceutical division